Improvement in prostate cancer survival over time: A 20-year analysis

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 1-8

  Kim, Michelle M ^a   Hoffman, Karen E ^a   Levy, Lawrence B ^a   Frank, Steven J ^a   Pugh, Thomas J ^a   Choi, Seungtaek ^a   Nguyen, Quynh N ^a   McGuire, Sean E ^a   Lee, Andrew K ^a   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer; improvement; Prostate; survival

Indexed keywords

ANDROGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CENTER; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT FAILURE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK FACTORS; SURVIVAL RATE; TEXAS; TREATMENT OUTCOME;

EID: 84863015655     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182467419     Document Type: Article

References (28)

1. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149. (Pubitemid 41095147)
2. Galper SL, Chen MH, Catalona WJ, et al. Evidence to support a cont-inued stage migration and decrease in prostate cancer specific mortality. JUrol. 2006;175:907-912. (Pubitemid 43200015)
3. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recur-rence-free survival following radical prostatectomy for clinically loca-lized prostate cancer. J Urol. 2001;166:416-419. (Pubitemid 32652213)
4. Newcomer LM, Stanford JL, Blumenstein BA, et al. Temporal trends in rates ofprostate cancer: declining incidence ofadvanced stage disease, 1974to 1994.JUrol. 1997;158:1427-1430. (Pubitemid 27391212)
5. Ung JO, Richie JP, Chen M, et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002;60:458-463. (Pubitemid 35292173)
6. Taneja SS. Imaging in the diagnosis and management ofprostate cancer. Rev Urol. 2004;6:101-113.
7. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67-74. (Pubitemid 350251041)
8. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106-1111.
9. Al-Mamgani A, Heemsbergen WD, Peeters ST, et al. Role of inte-nsity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685-691.
10. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study ofdose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br JCancer. 2005;92:488-498. (Pubitemid 40395529)
11. Hanks GE, Martz KL, Diamond JJ. The effect ofdose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988;15:1299-1305. (Pubitemid 19015470)
12. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome ofhigh dose intensity modulated radiation therapy for patients with clinically local-izedprostate cancer. J Urol. 2006;176:1415-1419. (Pubitemid 44307191)
13. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.Lancet London UK). 2002;360:103-106.
14. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289-295. (Pubitemid 351159365)
15. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression ad-juvant to definitive radiotherapy in prostate carcinoma-long-term results ofphase III RTOG 85-31. Int JRadiat Oncol Biol Phys. 2005; 61:1285-1290. (Pubitemid 40470408)
16. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. JClin Oncol. 2008;26:2497-2504.
17. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally adva-nced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-591. (Pubitemid 351264352)
18. Cooperberg MR, Grossfeld GD, Lubeck DP, et al. National practice patterns and time trends in androgen ablation for localized prostate ca-ncer. J Natl Cancer Inst. 2003;95:981-989. (Pubitemid 36896715)
19. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. V 4.2011. Available at: www.nccn.org. Accessed April 14, 2011.
20. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in m-en with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
21. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995. Bethesda, MD: SEER Program, National Cancer Institute; 1999.
22. Catalona WJ, Smith DS, Ratliff TL, et al. Detection oforgan-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954. (Pubitemid 23244733)
23. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates ofextraca-psular extension after radical prostatectomy: evidence for continued stagemigration. J Clin Oncol. 1999;17:3167-3172.
24. Master VA, Chi T, Simko JP, et al. The independent impact ofextended pattern biopsy on prostate cancer stage migration. J Urol. 2005;174: 1789-1793; discussion 1793. (Pubitemid 41546940)
25. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int JRadiat Oncol Biol Phys. 1997;39:1011-1018. (Pubitemid 27506151)
26. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radia-tion dose response: results of the M. D. Anderson phase III rando-mized trial. Int JRadiat Oncol Biol Phys. 2002;53:1097-1105. (Pubitemid 34787842)
27. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876-881. (Pubitemid 32750970)
28. Zietman AL, De Silvio ML, Slater JD, et al. Comparison ofconventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239. (Pubitemid 41352111)